Investigating Microglia’s Role In Alzheimer’s Pathology

Announcing a caller article publication for BIO Integration journal. Alzheimer's illness (AD) is simply a neurodegenerative upset and nan starring origin of dementia worldwide. Microglia, arsenic cardinal tense strategy (CNS) resident macrophages, are cardinal to AD pathology. Indeed, microglia aggregation astir amyloid-β (Aβ) deposits is an AD hallmark.

Triggering receptor expressed connected myeloid cells 2 (TREM2) regulates microglial function. TREM2 boosts microglial responses to AD pathologic damage, drives homeostatic activation, and modulates protective pathways.

Anti-human TREM2 agonist monoclonal antibody (hT2AB) serves arsenic an replacement TREM2 ligand and has therapeutic imaginable successful TREM2-mutant rodent models. This study mixed single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics to explain hT2AB molecular and cellular mechanisms successful improving AD and analyse microglial dynamics successful hT2AB-treated groups during AD progression.

Key functional subpopulations and halfway biomarkers were identified done pseudo-time analysis, compartment connection analysis, and transcription factors (TFs) pinch a attraction connected nan differentiation process of microglia towards a therapeutic phenotype, providing a theoretical ground and imaginable targets for optimizing AD treatment.

scRNA-seq, spatial transcriptomics, and deconvolution study depicted microglia successful AD. Differentially expressed genes underwent enrichment analyses. Pseudotemporal study demonstrated microglial move differentiation paths during AD progression and post-hT2AB treatment. The CellChat package constructed nan compartment connection network. Finally, pySCENIC study identified cardinal TFs successful cardinal subpopulations.

Seven functionally heterogeneous microglial subpopulations were identified pinch nan C2 subpopulation highly expressed successful nan hT2AB group subpopulation. The projected temporal series study revealed 2 chopped microglial compartment differentiation trajectories, some originating from nan C6 and C7 subpopulations and extending successful different directions starting from nan C2 subpopulation.

Lineage1-related subpopulations (C7-C6-C4-C2-C1-C5) erstwhile mixed pinch pathway activity scoring were confirmed to align pinch microglial translator toward protective phenotypes. This study besides identified halfway biomarkers that were highly expressed successful nan C2 subpopulation (the captious turning subpopulation of 2 trajectories). In addition, this study mixed nan spatial transcriptome information of AD rodent encephalon insubstantial sections, providing nonstop grounds for nan spatial distribution of cardinal compartment subpopulations and pathways.

This study identified nan C2 microglial subpopulation arsenic nan cardinal effector regulated by hT2AB successful AD pathology. hT2AB was confirmed to guideline microglia toward protective differentiation, providing cell-level nonstop grounds for nan therapeutic effect. The results deepen knowing of AD encephalon microglial heterogeneity and nan hT2AB system of action, offering reliable grounds for processing caller AD biomarkers and optimizing TREM2-targeted therapies, and is expected to amended AD objective outcomes.